Welcome to our dedicated page for Liquidia Corporation news (Ticker: LQDA), a resource for investors and traders seeking the latest updates and insights on Liquidia Corporation stock.
Liquidia Corporation (NASDAQ: LQDA) is a U.S.-based biopharmaceutical company committed to enhancing drug delivery and efficacy through its proprietary PRINT® technology. The company focuses on the development, manufacturing, and commercialization of innovative therapies for pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Liquidia’s flagship product, YUTREPIA™, is an investigational inhaled dry powder formulation of treprostinil designed to treat pulmonary arterial hypertension (PAH) and PH-ILD. This product aims to improve exercise ability and quality of life for patients.
Liquidia is actively advancing its product pipeline, which includes L606, an investigational sustained-release formulation of treprostinil administered through a next-generation nebulizer. Currently, L606 is under evaluation in an open-label study and aims to extend drug exposure while minimizing local irritation in the lungs.
In addition to these developments, Liquidia has a valuable collaboration with leading pharmaceutical companies, leveraging its PRINT® technology for broader therapeutic areas. This technology enables precise production of uniform drug particles, enhancing safety and efficacy, and can be applied to various therapeutic areas and routes of administration.
Recent achievements include the promotion of key leadership within the company as they prepare for the potential FDA approval and launch of YUTREPIA. The company has also successfully navigated regulatory and legal challenges, ensuring a clear path for YUTREPIA’s market entry.
Financially, Liquidia has demonstrated robust growth, reporting significant revenue from its partnership with Sandoz for the commercial sale of Treprostinil Injection. The company has also secured substantial funding through strategic agreements, bolstering its cash reserves for continued research and development efforts.
Liquidia remains dedicated to transforming patient care by addressing unmet needs with innovative drug delivery solutions and is poised to make significant strides in the biopharmaceutical industry.
Liquidia (NASDAQ: LQDA) reported Q3 2024 financial results, highlighting key developments including FDA tentative approval for YUTREPIA™ for PAH and PH-ILD treatments. Revenue increased to $4.4M from $3.7M year-over-year. The company strengthened its balance sheet by raising approximately $100M through equity offering and financing agreement. Net loss widened to $23.2M ($0.30 per share) compared to $15.8M ($0.24 per share) in Q3 2023. Cash position improved to $204.4M as of September 30, 2024. Launch of YUTREPIA is currently gated until May 23, 2025, due to TYVASO DPI's exclusivity period.
Liquidia (NASDAQ: LQDA), a biopharmaceutical company focused on rare cardiopulmonary disease treatments, has announced its upcoming presentation at the Stifel 2024 Healthcare Conference in New York City. The presentation is scheduled for Tuesday, November 19, 2024, from 3:00 to 3:30 p.m. ET.
Investors and interested parties can access the live webcast through Liquidia's website investor section. A recorded version will remain available on the company's website for at least 30 days after the event.
Liquidia (NASDAQ: LQDA), a biopharmaceutical company focused on rare cardiopulmonary disease therapies, has rescheduled its third quarter 2024 financial results announcement to November 13, 2024. The date change accommodates SEC filing rules affected by the November 11 federal holiday. The company will host a webcast at 8:30 a.m. Eastern Time to discuss results and provide a corporate update. The webcast will be accessible on Liquidia's website and archived for one year.
Liquidia (NASDAQ: LQDA), a biopharmaceutical company focused on rare cardiopulmonary disease therapies, has scheduled its third quarter 2024 financial results announcement for November 11, 2024. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss financial performance and provide a corporate update. The webcast will be accessible through Liquidia's website and will remain archived for one year.
The U.S. Supreme Court has rejected United Therapeutics' petition to appeal previous rulings that invalidated all claims of U.S. Patent No. 10,716,793 ('793 Patent). This decision finalizes the Patent Trial and Appeal Board's July 2022 ruling, affirmed by the Federal Circuit in December 2023, making the '793 patent unenforceable. Liquidia (NASDAQ: LQDA) received tentative FDA approval for YUTREPIA on August 16, 2024, to treat PAH and PH-ILD in adults. Final approval may occur after May 23, 2025, when Tyvaso DPI's regulatory exclusivity expires. No patents currently prevent YUTREPIA's final FDA approval. A separate lawsuit regarding U.S. Patent No. 11,826,327 is scheduled for trial in June 2025.
Liquidia (NASDAQ: LQDA) and Pharmosa Biopharm have expanded their collaboration for the development and commercialization of L606, an inhaled, sustained-release formulation of treprostinil for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The amended agreement extends Liquidia's licensed territory beyond North America to include key markets in Europe, Japan, and elsewhere.
Liquidia will pay Pharmosa a $3.5 million upfront payment and up to $157.75 million in additional milestone payments. The collaboration includes rights to Pharmosa's next-generation smart-technology nebulizers. Clinical data for L606 has shown encouraging results, with favorable tolerability and a pharmacokinetic profile supporting twice-daily administration.
Liquidia (NASDAQ: LQDA) announced its participation in the CHEST 2024 annual meeting hosted by the American College of Chest Physicians on October 6-9, 2024, in Boston. The company will present a poster and host a medical theater at the event. The poster, titled "Baseline Characteristics of Patients Enrolled in the ASCENT Study: Evaluating Safety and Tolerability of YUTREPIA™, A Dry Powder Inhaled Treprostinil in Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)," will be presented on October 9th. It will focus on Liquidia's ongoing clinical trial, dosing and tolerability profiles, and exploratory efficacy endpoints for YUTREPIA in PH-ILD patients.
The medical theater, scheduled for October 7th, will discuss current epidemiologic data on PH-ILD, the clinical data gap regarding dry-powder treprostinil use in PH-ILD, and how Liquidia's ASCENT study is addressing this gap, as well as the future of PH-ILD treatments.
Liquidia (NASDAQ: LQDA) announced that the U.S. District Court for New Jersey has found United Therapeutics' interference with the launch of generic Treprostinil Injection caused losses exceeding $137 million. This decision stems from a 2019 lawsuit filed by Liquidia PAH and Sandoz against United Therapeutics, alleging violations of antitrust laws and unfair competition. The court granted partial summary judgments in March 2022 and has now determined damages from the breach of contract by United Therapeutics.
The final damage award is yet to be determined and will be offset by costs avoided by Sandoz. Proceeds from the litigation will be split equally between Sandoz and Liquidia PAH, with Liquidia PAH's share further divided between Henderson SPV, and PBM RG Holdings, due to litigation finance agreements.
Liquidia (NASDAQ: LQDA) has announced significant financial developments, including:
1. A $67.5 million raise through an underwritten public offering and a concurrent private placement, offering shares at $8.90 per share.
2. An additional $32.5 million funding from HealthCare Royalty (HCRx) through an amendment to their Revenue Interest Financing Agreement (RIFA).
These actions will provide Liquidia with approximately $100 million in gross proceeds. The funds will support the ongoing commercial development of YUTREPIA™ for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), as well as other clinical trials and the development of L606.
Bronstein, Gewirtz & Grossman, is investigating potential claims against Liquidia Technologies, Inc. (NASDAQ:LQDA) on behalf of shareholders. The investigation follows Liquidia's announcement on August 19, 2024, that the FDA granted tentative approval for YUTREPIA™ (treprostinil) inhalation powder for treating PAH and PH-ILD in adults. However, final approval is delayed due to a competing product's regulatory exclusivity.
Following this news, Liquidia's stock price fell 30.62%, closing at $9.79 per share. Investors who purchased Liquidia securities are encouraged to assist the investigation. The law firm is representing investors on a contingency fee basis, seeking reimbursement for expenses and attorneys' fees only if successful.
FAQ
What is the current stock price of Liquidia Corporation (LQDA)?
What is the market cap of Liquidia Corporation (LQDA)?
What is Liquidia Corporation's primary focus?
What is YUTREPIA?
What is PRINT® technology?
What products are in Liquidia’s pipeline?
How does Liquidia generate revenue?
What recent leadership changes have occurred at Liquidia?
What is the current status of YUTREPIA’s FDA approval?
What are the financial highlights for Liquidia?
What legal challenges has Liquidia faced?
How can I learn more about Liquidia Corporation?
